key: cord-0777315-xtvviz3t authors: Lê, Minh Patrick; Peiffer-Smadja, Nathan; Guedj, Jeremie; Neant, Nadège; Mentré, France; Ader, Florence; Yazdanpanah, Yazdan; Peytavin, Gilles title: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial—authors’ response date: 2020-10-22 journal: J Antimicrob Chemother DOI: 10.1093/jac/dkaa415 sha: 93264a6fcb6c3d97afb426757c48e9d8371ca589 doc_id: 777315 cord_uid: xtvviz3t nan *Corresponding author. E-mail: minh.le@aphp.fr †Members are listed in the Acknowledgements section. Sir, We thank Mégarbane and Scherrmann 1 for taking valuable time to comment on our article 2 and the JAC Editorial Board for providing us with an opportunity to respond. With hindsight, we are keenly aware of the rapid advances in knowledge concerning hydroxychloroquine treatment for COVID-19 and, thus, of the limitations of the assumptions underlying our dose regimen. To place all of this in context, our objective in writing Lê et al. 2 was, firstly, to justify the use of a loading dose of hydroxychloroquine with respect to its pharmacokinetic characteristics. At the start of the COVID-19 pandemic in France, the doses of hydroxychloroquine sulphate used were mostly derived from those used for the indication of chronic autoimmune disease treatment, with no loading dose and even three administrations per day. 3 For the record, the dose we proposed to evaluate in the C-20-15 DisCoVeRy trial (beginning 22 March 2020) was 400 mg twice daily on day 1 and then 400 mg once daily from days 2 to 10. This choice of dose regimen was based on an acceptable benefit/risk ratio in the context of the pandemic. A number of other trials have also since chosen to evaluate the same hydroxychloroquine dose regimen (www.clinicaltrials.gov). Most of the arguments put forward in Mégarbane and Scherrmann 1 are based on findings published after the start of the C-20-15 DisCoVeRy trial and, thus, on previously unavailable pharmacokinetic, virological and safety evidence. We agree with some of the theoretical comments, concerning which optimal EC 90 anti-SARS-CoV-2 activity marker should be considered, for example, but we preferred to use EC 50 , which is sometimes the only available parameter, is probably easier to obtain in studies in vitro and is used in physiologically based pharmacokinetic simulations. Surprisingly, Mégarbane and Scherrmann 1 passed over the recent evaluation of the antiviral activity of hydroxychloroquine both in vitro and in SARS-CoV-2-infected non-human primates. 4 The dose-dependent in vitro antiviral activity of hydroxychloroquine against SARS-CoV-2 (IC 50 values of 2.2 and 4.4 lM at 48 and 72 h post infection, respectively) was demonstrated in cultured Vero E6 cells, but doses of 1-10 lM hydroxychloroquine failed to decrease SARS-CoV-2 apical viral titres at 48 h post infection in the MucilAir TM reconstituted human airway epithelium model. This study also showed hydroxychloroquine treatment with a loading dose (with or without azithromycin) to have no clinical efficacy in cynomolgus macaques, regardless of the timing of treatment initiation with respect to SARS-CoV-2 inoculation, despite high hydroxychloroquine concentrations in blood and lung, with blood exposure similar to that in COVID-19 patients receiving hydroxychloroquine. Moreover, this study reported a lung:plasma ratio of 27:177, suggesting a rapid accumulation of hydroxychloroquine in this compartment. Interestingly, regarding the lack of a clear relationship between QTc prolongation and hydroxychloroquine blood exposure or daily or cumulative doses, Mégarbane and Scherrmann 1 did not address the difficulty of attributing adverse effects in the midst of a cytokine storm or the issue of synergistic cardiac toxicity with second-generation macrolides. Several studies have highlighted concerns about the safety of combinations of azithromycin and hydroxychloroquine. [5] [6] [7] Mégarbane and Scherrmann 1 also seem unsurprised by the very high mortality (25.7%) for the hydroxychloroquine arm in the Recovery trial (primary endpoint at 28 days, not significantly different from the 23.5% for usual care). The possibility of high-dose toxicity (2400 mg on day 1 and 400 mg q12h up to day 10), which could have masked a low antiviral activity of hydroxychloroquine, is not even mentioned. The recent in silico study by Garcia-Cremades et al. 8 cited by Mégarbane and Scherrmann 1 estimated a plasma concentration of 4.7 lM (1578 lg/L) for 50% viral inhibition. This concentration (close to the in vitro EC 50 ), which might decrease viral load more rapidly, decrease the proportion of infected patients and shorten the duration of treatment, is also dangerously close to the toxic range of plasma concentrations for hydroxychloroquine. 9 It would be even closer to the limit if the model estimated an in vivo EC 90 . In conclusion, the repurposing of a drug for a different indication seems to be more complex than simply changing the dose. The most relevant of the available models is probable non-human primates, if the animals can tolerate the equivalent human drug. In vitro models seem to be very different, with the exception of SARS-CoV-2-infected lung epithelial cell cultures. 10 Although the V C The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. maximal effect of the dose may not have been reached, our rationale highlights the major limitation of the narrow therapeutic index of hydroxychloroquine, with important safety concerns, particularly as the objective was to validate the use of a hydroxychloroquine dose regimen in the general population. Unfortunately, the discontinuation of the C-20-15 DisCoVeRy trial, for reasons of futility, has prevented us from further evaluating our hydroxychloroquine dose regimen and drawing conclusions about the true antiviral efficacy of hydroxychloroquine in humans. Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for QT interval monitoring Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing Treatment of hydroxychloroquine overdose Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection We thank Julie Sappa (Alex Edelman Associates) for her editorial support. F.M. has acted as a consultant for Novartis, Ipsen, Servier and Da Volterra, and has received research grants from Roche and Sanofi (outside the submitted work). G.P. has received travel grants, consultancy fees, honoraria or study grants from various pharmaceutical companies, including Gilead Sciences, Merck, Pharmatechnologie and ViiV Healthcare. All other authors: none to declare.